Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection

Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma-reactive T cells at the primary site of melano...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Kambayashi, Yumi, Sato, Yota, Tanita, Kayo, Amagai, Ryo, Hashimoto, Akira, Hidaka, Takanori, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607934/
https://www.ncbi.nlm.nih.gov/pubmed/31297373
http://dx.doi.org/10.3389/fmed.2019.00140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607934/
https://www.ncbi.nlm.nih.gov/pubmed/31297373
http://dx.doi.org/10.3389/fmed.2019.00140

Ejemplares similares